Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins

Cancer Research

Volumn 56, Issue 6, 1996, Pages 1283-1290

  Dehal, Shangara S ^a   Kupfer, David ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYTAMOXIFEN; CATECHOL DERIVATIVE; DRUG METABOLITE; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COVALENT BOND; DRUG DETERMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOTRANSFORMATION; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HYDROXYLATION; MALE; MICROSOMES, LIVER; PHENOBARBITAL; PREGNENOLONE CARBONITRILE; RATS; RATS, SPRAGUE-DAWLEY; S-ADENOSYLHOMOCYSTEINE; S-ADENOSYLMETHIONINE; TAMOXIFEN;

EID: 0029866506     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Jordan, V C The development of tamoxifen for breast cancer therapy a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat , 11: 197-209, 1988.
2. Jordan, V. C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol., 110, 507-517, 1993
3. Chlebowski, R J , Butler, J , Nelson, A., and Lillington, L Breast cancer chemoprevention. Tamoxifen current issues and future perspective. Cancer (Phila), 72: 1032-1037, 1993.
4. Fisher, B , and Redmond, C New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl. Cancer Inst., 83: 1278-1280, 1991
5. Wold, M. D., and Jordan, V. C Therapeutic efficacy, side effects and the potential for tamoxifen to prevent breast cancer In: M K Agarwal (ed), Antihormones in Health and Disease, Vol. 19, pp 87-98. Basel: S. Karger AG, 1991
6. Jordan, V. C. The role of tamoxifen in the treatment and prevention of breast cancer. Current Probl Cancer, 16: 129, 1992.
7. Dauplat, J., LeBouedec, G., and Achard, J L. Endometrial adenocarcinoma in 2 patients taking tamoxifen. Presse Med., 19, 380-381, 1990.
8. Killackey, M A , Hakes, T. B., and Price, V. K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens Cancer Treat Rep., 69: 237-238, 1985.
9. Fornander, T., Cedermark, B., Matteson, A , Skoog, L , Theve, T , Askergren, J , Ratqvist, L. E., Glas, U , Silljverswaard, C., Somell, A , Wilking, N., and Hjolmar, M. J Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers Lancet, 1: 117-119, 1989.
10. Fendel, K. C , and Zimmski, S J Role of tamoxifen in the induction of hormone-independent rat mammary tumors Cancer Res., 52, 235-237, 1992.
11. Williams, G M., Iatropoulos, M J., Djordjevic, M. W., and Kaltenberg, O P. The triphenylethylene drug tamoxifen is a strong carcinogen in the rat Carcinogenesis (Lond.), 14 315-317, 1993
12. Metzler, M., and Schiffmann, D. Structural requirements for the in vitro transformation of syrian hamster embryo cells by stilbene estrogens and triphenylethylene-type antiestrogens. Am. J. Clin. Oncol., 14 (Suppl. 2), 530-535, 1991.
13. Vancutsem, P. M., Lazarus, P., and Williams, G. M. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res., 54: 3864-3867, 1994.
14. Lyman, S. D., and Jordan, V. C Metabolism of non-steroidal antiestrogens. In: V. C. Jordan (ed.), Metabolism of Non-steroidal Antiestrogens in Estrogen/Antiestrogen Action and Breast Cancer Therapy, pp 191-219. Madison, WI. The University of Wisconsin Press, 1986.
15. Foster, A. B., Griggs, L. J., Jarman, M., vanMaanen, M. S., and Schulten, H-R. Metabolism of tamoxifen by rat liver microsomes: formation of the oxide, a new metabolite. Biochem. Pharmacol , 29, 1977-1979, 1980.
16. Reunitz, P. C., Bagley, J. R., and Pape, C. W. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab. Dispos., 12: 478-483, 1984.
17. McCague, R., and Seago, A Aspects of metabolism of tamoxifen by rat liver microsomes. Biochem. Pharmacol., 35: 827-834, 1986.
18. Mani, C., Gelboin, H. V., Park, S. S., Pierce, R., Parkinson, A., and Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos., 21: 645-656, 1993.
19. Lim, C. K., Yuan, Z-X., Lamb, J. H., White, I N. H., De Matteis, F., and Smith, L. L. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes Carcinogenesis (Lond.). 15: 589-593, 1994
20. 2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer Drug Metab Dispos., 23: 377-382, 1995.
21. Phillips, D. H., Carmichael, P L., Hewer, A , Cole, K. J., and Poon, G. K. α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res , 54: 5518-5522, 1994.
22. Poon, G. K., Chui, Y C., McCague, R , Lonning, P. E., Feng, R., Rowlands, M. G., and Jarman, M. Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos., 21, 1119-1124, 1993.
23. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., Okuda, K., and Nebert, D. W. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol., 12: 1-51, 1993.
24. Jacolot, F , Simon, I , Dreano, Y., Beaune, P., Riche, C , and Berthou, F. Identification of the cytochrome P-450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41: 1911-1919, 1991.
25. Mani, C., Hodgson, E., and Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos., 21: 657-661, 1993.
26. AA as catalyst of 4-hydroxylation induced by TCDD and βNF. Cancer Res., 54:3140-3144, 1994.
27. Mani, C , and Kupfer, D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res , 51: 6052-6058, 1991.
28. Mani, C., Pierce, R., Parkinson, A., and Kupfer, D. Involvement of cytochrome P-4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis (Lond), 15: 2715-2720, 1994.
29. Han, X-L., and Liehr, J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52: 1360-1363, 1992.
30. White, I. N H , de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C , Venitt, S., Hewer, A. and Phillips, D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats DBA/2 and C57B1/G mice and in human MCL-5 cells. Carcinogenesis (Lond), 13: 2197-2203, 1992.
31. Pathak, D. N , and Bodell, W. J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation system. Carcinogenesis (Lond.), 15: 529-532, 1994.
32. Randerath, K., Bi, J., Mabon, N , Sriram, P., and Moorthy, B. Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatmem with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis (Lond.), 15: 797-800, 1994.
33. Dehal, S. S., Mani, C., and Kupfer, D. Covalent binding of tamoxifen and its metabolites: 4-hydroxytamoxifen a proximate species to the reactive intermediate in rats and humans. Int. Soc. Stud. Xenobiotics Proc , 6, 160, 1994.
34. Burstein, S. H., and Kupfer, D. Hydroxylation of trans-δ-tetrahydrocannabinol by hepatic microsomal oxygenase. Ann. NY Acad. Sci., 191: 61-67, 1971.
35. Lowry, O. H., Rosebrough, N J., Farr, A. L , and Randall, R. J. Protein measurement with the Folin phenol reagent. J Biol Chem., 193: 265-275, 1951.
36. Stauffer, C. E. A linear standard curve for the Folin-Lowry determination of protein. Anal. Biochem., 69, 646-648, 1975.
37. Juedes, M. J., Bulger, W. H., and Kupfer, D. Monooxygenase-mediated activation of chlorotrianisene (TACE) in covalent binding to rat hepatic microsomal proteins. Drug Metab Dispos , 15 786-793, 1987.
38. 14C-methoxychlor metabolite(s) to rat liver microsomal components. Toxicol Appl. Pharmacol., 68: 367-374, 1983.
39. Li, S. A., Purdy, R. H , and Li, J. J Variations in catechol O-methyltransferase in rodent tissues: possible role in estrogen carcinogenicity. Carcinogenesis (Lond.), 10 63-67, 1989.
40. Hoffman, A. R., Paul, S. M., and Axelrod, J. Estrogen-2-hydroxylase in the rat. Biochem Pharmacol., 29: 83-87, 1980
41. Kupfer, D., Bulger, W. H., and Theoharides, A. D. Metabolism of methoxychlor by hepatic P-450 monooxygenases in rat and human. 1. Characterization of a novel catechol metabolite. Chem. Res. Toxicol, 3: 8-16, 1990.
42. 2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos , 23: 377-382, 1995
43. Abul-Hajj, Y. J., Tabakovic, K , and Tabakovic, I. An estrogen-nucleic acid adduct Electroreductive intermolecular coupling of 3: 4-estrone-o-quinone with adenine. J. Am. Chem. Soc., 117: 6144-6145, 1995.
44. Nelson, S D. Metabolic activation and drug toxicity. J. Med. Chem., 25: 753-765, 1982
45. Jordan, V C., Collins, M. M , Rowsby, L., and Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J. Endocrinol., 75 305-316, 1977.
46. Borgna, J-L., and Rochefort, H Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem., 256: 859-868, 1981.
47. Furr, B. J. A., and Jordan, V. C. The pharmacology and clinical uses of tamoxifen Pharmacol. & Ther., 25: 127-205, 1984.
48. Malet, C., Compel, A., Spritzer, P., Bricout, N., Yaneva, H., Mowszowicz, I , Kuttenn, F , and Mayvais-Jarvis, P. Tamoxifen and hydroxytamoxifen isomere versus estradiol effects on normal human breast cells in culture. Cancer Res., 48, 7193-7199, 1988.
49. Vignon, F , Bouton, M-M., and Rochefort, H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem. Biophys. Res. Commun., 146: 1502-1508, 1987.
50. Coezy, E., Borgna, J. L., and Rcchefort, H. Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res., 42: 317-323, 1982.
51. Pathak, D. N , Pongracz, K., and Bodell, W J. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts, comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis (Lond.), 16: 11-15, 1995.
52. Fischer, B., Costantino, J P., Redmond, C. K., Fisher, E. R., Wickerham, D. L , and Cronin, W. M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst., 86: 527-537, 1994.
53. van Leeumne, F. E., Benraadt, J., Coebergh, J. W W., Kiemeney, L. A. L. M., Gimbrere, C. H. F., Otter, R., Schouten, L. J., Damhuis, R. A M., Bontenbal, M , Diepenhorst, F W., van den Belt-Dusebout, A W., and van Tinteren, H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet, 343: 448-152, 1994
54. Phillips, D. H., Hewer, A., White, I. N. H., and Farmer, P. B. Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis (Lond.), 15: 793-795, 1994
55. Pongracz, K., Pathak, D. N., Nakamura, T. Burlingame, A L., and Bodell, W J. Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res. 55: 3012-3015, 1995
56. Heuman, D. M., Gallagher, E. J., Barwick, J. L , Elshourbafy, N. A., and Guzelian, P. S. Immunochemical evidence for induction of a common form of hepatic cytochrome P450 in rats treated with pregnenolone-16α-carbonitrile or other steroidal or non-steroidal agents. Mol. Pharmacol., 21, 753-760, 1982.
57. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved Biochem. Pharmacol, 49: 1035-1042, 1995.
58. Ryan, D. E., and Levin, W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol. & Ther., 45: 153-239, 1990.
59. White, I N. H , Davis, A., Smith, L. L., Dawson, S., and de Matteis, F Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol , 45: 21-30, 1993
60. Nuwaysir, E. F., Dragon, Y P , Jefcoate, C. R , Jordan, V C., and Pitot, H. C Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver Cancer Res , 55: 1780-1786, 1995.
61. Soucek, P. and Gut, I Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica, 22: 83-103, 1992.
62. Mimura, M., Baba, T., Yamazaki, H., Ohmori, S , Inui, Y., Gonzalez, F J., Guengerich, F P, and Shimada, T Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos , 21: 1048-1056, 1993
63. Liehr, J G. Mechanisms of metabolic activation and inactivation of catecholestrogens: a basis of genotoxicity Polycyclic Aromatic Compounds, 6: 229-239, 1994.
64. Liehr, J G , and Roy, D. Free radical generation by redox cycling of estrogens Free Radical Biol. & Med., 8: 415-423, 1990
65. Sawahata, T., and Neal, R. A. Biotransformation of phenol to hydroquinone and catechol by rat liver microsomes. Mol. Pharmacol, 23: 453-460, 1983.
66. Turner, M J., III, Fields, C. E , and Everman, D B. Evidence for superoxide formation during hepatic metabolism of tamoxifen Biochem. Pharmacol., 41 1701-1705, 1991.